Incretin analogs and their uses
By using incretin analogs with balanced activity at GIP, GLP-1, and GCG receptors, the side effects and frequent dosing problems of existing incretin analogs have been solved, achieving low-frequency dosing and effective glycemic control and weight loss.
Patent Information
- Application Number
- CN202080087802.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-18
- Filing Date
- 2020-12-11
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-12-11
AI Technical Summary
Existing GLP-1 analogs have limitations in treating type 2 diabetes due to gastrointestinal side effects and require frequent dosing, making them ineffective in controlling blood sugar and weight loss. Furthermore, existing incretin analogs have an imbalance of activity at multiple receptors, leading to side effects and high treatment frequency.
Develop incretin analogs that are active at GIP, GLP-1 and GCG receptors, providing balanced activity and prolonged duration of action through conjugation of specific amino acid sequences and fatty acid moieties, allowing for low-frequency dosing.
It achieves balanced activity at GIP, GLP-1 and GCG receptors, reduces side effects, and enables low-frequency dosing once a week or longer by extending the duration of action, thus improving glycemic control, weight loss and metabolic benefits.
Smart Images

Figure 27321DEST_PATH_IMAGE010 
Figure 49821DEST_PATH_IMAGE012 
Figure 127050DEST_PATH_IMAGE022
Abstract
Description
[0001] The present disclosure relates to incretin analogs that are active at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors. The incretin analogs herein have structural features that provide balanced activity at each of these receptors and have an extended duration of action. Such incretin analogs can be used to treat conditions, diseases, and disorders including type 2 diabetes (T2DM), dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and / or obesity, as well as cardiovascular diseases and neurodegenerative diseases that are not considered metabolic diseases.
[0002] Over the past few decades, the prevalence of diabetes has been increasing. T2DM is the most common form of diabetes, constituting approximately 90% of all diabetes. T2DM is characterized by high blood sugar levels caused by insulin resistance. The current standard of care for T2DM includes diet and exercise, as well as oral and injectable hypoglycemic agents, including incretin-based therapies, such as GLP-1 receptor agonist treatment.
[0003] GLP-1 is a 36-amino acid peptide, the major biologically active fragment of which is a 30-amino acid C-terminal amidated peptide (GLP-1 7-36 ; SEQ ID NO: 2), which stimulates glucose-dependent insulin secretion and prevents hyperglycemia in diabetic patients. Various GLP-1 analogs are currently available for the treatment of T2DM, including dulaglutide, exenatide and liraglutide. However, many of the currently available GLP-1 analogs are dose-limited by gastrointestinal side effects such as nausea and vomiting. When oral medications and incretin-based therapies are insufficient for treatment, insulin treatment is considered. Despite the treatment options available, a significant number of individuals receiving approved therapies do not achieve glycemic control goals (see, e.g., Casagrande et al. (2013) Diabetes Care 36:2271-2279).
[0004] Uncontrolled diabetes mellitus can lead to one or more conditions that affect morbidity and mortality in these individuals. One of the major risk factors for T2DM is obesity, and many patients with T2DM (~90%) are overweight or obese. It has been documented that a reduction in body adiposity leads to improvements in obesity-related comorbidities, including hyperglycemia and cardiovascular events. Therefore, better disease management requires therapies that effectively control blood sugar and reduce weight.
[0005] In view of this, new therapies studied include compounds that are active not only at the GLP-1 receptor but also at one or more other receptors such as GIP and / or GCG receptors. In fact, some compounds have been described as having triple receptor agonist activity (i.e., activity at each of the GIP, GLP-1, and GCG receptors). For example, International Patent Application Publication No. WO2015 / 067716 describes GCG analogs with triple receptor agonist activity. Similarly, International Patent Application Publication No. WO 2016 / 198624 describes exendin-4 analogs with triple receptor agonist activity. Similarly, International Patent Application Publication Nos. WO 2014 / 049610 and WO 2017 / 116204 each describe various compounds with triple receptor agonist activity. In addition, International Patent Application Publication No. WO 2017 / 153375 describes GCG and GLP-1 co-agonists that are also claimed to have GIP receptor agonist activity.
[0006] Although commonly used to treat T2DM, incretins and their analogs that are active at one or more of the GIP, GLP-1 and / or GCG receptors have also been described as having potential therapeutic value in many other conditions, diseases or disorders, including, for example, Alzheimer's disease, bone-related disorders, dyslipidemia, metabolic syndrome, NAFLD and NASH, obesity and Parkinson's disease. See, for example, Jall et al. (2017) Mol. Metab. 6:440-446; Carbone et al. (2016) J. Gastroenterol. Hepatol. 31:23-31; Finan et al. (2016) Trends Mol. Med. 22:359-376; Choi et al. (2017) Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1 / Glucagon / GIP triple-agonist (HM15211) , ADA Poster1139-P; Ding (2008) J. Bone Miner. Res. 23:536-543; Tai et al. (2018) Brain Res. 1678:64-74; Müller et al. (2017) Physiol. Rev. 97:721-766; Finan et al. (2013) Sci. Transl. Med. 5:209; Hölscher (2014) Biochem. Soc. Trans. 42:593-600.
[0007] However, there remains a need for treatments for these conditions, diseases and disorders, particularly T2DM, that provide effective glycemic control, have weight loss benefits and / or a favorable side effect profile. There is also a need for therapeutic agents that can be used with a sufficiently long duration of action to allow for low-frequency dosing, such as once daily, three times a week, twice a week, or once a week.
[0008] The incretin analogs herein attempt to meet the above needs. Accordingly, the present disclosure describes incretin analogs that are active at each of the GIP, GLP-1, and GCG receptors. Advantageously, the incretin analogs herein have balanced activity at these receptors, thereby allowing the given dose to provide sufficient activity at each receptor to provide the agonist benefit of the receptor while avoiding undesirable side effects associated with too high activity. In addition, the incretin analogs herein have an extended duration of action at each of the GIP, GLP-1, and GCG receptors to allow low-frequency dosing such as once a day, three times a week, twice a week, or once a week. In this way, the incretin analogs bring enhanced glycemic control, metabolic benefits such as weight loss and / or improved body composition, lipid benefits such as reduced proprotein convertase subtilisin / kexin type 9 (PCSK9), and / or other benefits such as increased bone mass or bone formation or reduced bone resorption. The present disclosure also describes effective treatments for conditions, diseases and disorders including T2DM, dyslipidemia, metabolic syndrome, NAFLD, NASH and / or obesity.
[0009] Accordingly, the present disclosure first describes an incretin analog or a pharmaceutically acceptable salt thereof, wherein the incretin analog comprises the following base amino acid sequence:
[0010]
[0011] Where X2 is Aib, X6 is αMeF(2F), X 10 Is Y or 4Pal, X 13 is L or αMeL, X 16 It's O, X 17 is any amino acid having a functional group available for conjugation, and the functional group is conjugated to C 16 -C 22 On the fatty acid part, X 20 is 4Pal, Iva or αMeL, X 21 is A or Aib, X 24 It is E or e, X 25 is Y or αMeY, and X 39is E or S (SEQ ID NO: 5), and wherein the carboxyl terminal (C-terminal) amino acid is optionally amidated.
[0012] In some cases, at position X 17 The amino acid with a functional group available for conjugation is C, D, E, K or Q. In some cases, at position X 17 The amino acid having a functional group available for conjugation is K.
[0013] In some cases, X2 is Aib, X6 is αMeF(2F), X 10 It is Y, X 13 Yes L, X 16 It's O, X 17 It is K, X 20 It is 4Pal, X 21 It's A, X 24 Yes E, X 25 is Y and X 39 is E, so that the incretin analog comprises the following base amino acid sequence:
[0014] .
[0015] In some cases, X2 is Aib, X6 is αMeF(2F), X 10 It is Y, X 13 It is αMeL, X 16 It's O, X 17 It is K, X 20 It's Iva, X 21 It's A, X 24 Yes E, X 25 is αMeY and X 39 is S, so that the incretin analog comprises the following base amino acid sequence:
[0016]
[0017] .
[0018] In some cases, X2 is Aib, X6 is αMeF(2F), X 10 It is 4Pal, X 13 It is αMeL, X 16 It's O, X 17 It is K, X 20 It is αMeL, X 21 It's Aib, X 24 It is e, X 25 is αMeY and X 39 is S, so that the incretin analog comprises the following base amino acid sequence:
[0019]
[0020] .
[0021] In some cases, C 16 -C 22 The fatty acid moiety is conjugated to an amino acid having a functional group available for conjugation via a linker. 16 -C 22 The fatty acid portion has the structure -CO-(CH2) a -CO2H, wherein a is an integer from 16 to 22. In some cases, the fatty acid moiety is C 18 Diacid or C 20 Likewise and in some cases, the linker is one or more units of [2-(2-amino-ethoxy)-ethoxy]]-acetyl (AEEA), aminohexanoic acid (Ahx), E, γ-glutamic acid (γE), or a combination thereof.
[0022] In certain cases, the incretin mimetics herein, including the linker and fatty acid moiety, can be one of the following:
[0023]
[0024] (SEQ ID NO:9),
[0025]
[0026] (SEQ ID NO: 10), or
[0027]
[0028] (SEQ ID NO: 11).
[0029] Secondly, a pharmaceutical composition is described, which comprises at least one incretin analogue herein or a pharmaceutically acceptable salt thereof (eg, trifluoroacetate, acetate or hydrochloride) and a pharmaceutically acceptable carrier. In some cases, the pharmaceutical composition may further comprise a carrier, a diluent and / or an excipient.
[0030] Third, methods for treating diseases such as T2DM, dyslipidemia, metabolic syndrome, NAFLD, NASH and obesity are described. Such methods may include at least the step of administering an effective amount of an incretin analog described herein to an individual in need thereof. In some cases, the disease is T2DM, NAFLD, NASH or obesity. In other cases, the disease is a cardiovascular disease and a neurodegenerative disease that are not considered a metabolic disease.
[0031] In some cases, the at least one incretin analog described herein may be administered subcutaneously (SQ) to an individual. Likewise and in some cases, the at least one incretin analog may be administered daily, every other day, three times a week, twice a week, once a week (i.e., weekly), once every two weeks (i.e., every other week), or once a month. In some cases, the at least one incretin analog may be administered subcutaneously every other day, three times a week, twice a week, once a week, every other week, or once a month. In specific cases, the at least one incretin analog is administered subcutaneously once a week (QW).
[0032] The method may further comprise the steps of measuring or obtaining the individual's weight or body composition and / or blood glucose and / or blood insulin and / or hemoglobin A1c (HbA1c) and / or blood lipids, and then comparing the values thus obtained with one or more baseline values or previously obtained values to assess the effectiveness of the treatment.
[0033] In some cases, the individual is obese or overweight. In other cases, the individual is a patient with diabetes (PwD), especially T2DM. In some cases, the individual is obese with T2DM, or overweight with T2DM.
[0034] The method may also be combined with diet and exercise and / or may be combined with additional therapeutic agents.
[0035] Fourth, incretin analogs are described for use in therapy, such as for the treatment of diseases such as T2DM, dyslipidemia, metabolic syndrome, NAFLD, NASH and obesity. In some cases, the disease is T2DM, NAFLD, NASH or obesity. In other cases, the disease is cardiovascular disease and neurodegenerative disease that are not considered metabolic diseases.
[0036] Fifth, the use of the incretin analogs herein in the preparation of a medicament for treating T2DM, dyslipidemia, metabolic syndrome, NAFLD, NASH and obesity is described. In some cases, the disease is T2DM, NAFLD, NASH or obesity. In other cases, the disease is cardiovascular disease and neurodegenerative disease that are not considered metabolic diseases.
[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of incretin analogs, pharmaceutical compositions, and methods, preferred methods and materials are described herein.
[0038] Furthermore, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the element. The indefinite article "a" or "an" thus generally means "at least one".
[0039] definition
[0040] As used herein, "about" means within a statistically significant range of a value, such as a specified concentration, length, molecular weight, pH, sequence identity, time range, temperature, or volume. Such a value or range may be on the order of typically within 20%, more typically within 10%, and more typically within 5% of a given value or range. The tolerances encompassed by "about" depend on the particular system under investigation and are readily recognized by those skilled in the art.
[0041] As used herein and with respect to one or more of the GIP, GLP-1 or GCG receptors, "activity," "activation," "activation," and the like refer to the ability of a compound, such as the incretin analogs herein, to bind to the receptor and induce a response at the receptor as measured using assays known in the art, such as the in vitro assays described below.
[0042] As used herein, "amino acid" refers to a molecule characterized from a chemical point of view by containing one or more amine groups and one or more carboxylic acid groups and may contain other functional groups. As known in the art, there is a group of 20 amino acids designated as standard amino acids and used as the structural unit of most peptides / polypeptides / proteins produced by any organism.
[0043] As used herein, "amino acid having a functional group available for conjugation" refers to any standard or non-standard amino acid having a functional group that can be conjugated to a fatty acid moiety, for example, via a linker. Examples of such functional groups include, but are not limited to, alkynyl, alkenyl, amino, azido, bromo, carboxyl, chloro, iodo, and sulfhydryl groups. Additionally, examples of standard amino acids that include such functional groups include C (sulfhydryl), D (carboxyl), E (carboxyl), K (amino), and Q (amide).
[0044] As used herein, an "analog" refers to a compound, such as a synthetic peptide or polypeptide, that activates a target receptor and elicits at least one in vivo or in vitro effect elicited by a natural receptor agonist.
[0045] As used herein, "cardiovascular disease that is not considered a metabolic disease" and the like refer to diseases such as atherosclerosis or heart failure.
[0046] The “C 16 -C 22 "Fatty acid" refers to a carboxylic acid having 16 to 22 carbon atoms. 16 -C 22Fatty acids can be saturated monoacids or saturated diacids ("diacids" have carboxyl groups at each end).
[0047] As used herein, "effective amount" refers to the amount, concentration or dosage of one or more incretin analogs herein or pharmaceutically acceptable salts thereof that provides the desired effect (i.e., produces a clinically measurable difference in the individual's condition, such as a reduction in blood glucose, a reduction in HbA1c, a reduction in body weight or body fat, and / or a change in body composition) in such individual being diagnosed or treated when administered in a single or multiple doses to such individual in need thereof. The effective amount is readily determined by one skilled in the art using known techniques and by observing the results obtained under similar circumstances. In determining the effective amount for an individual, many factors are considered, including, but not limited to, the species of mammal, its size, age and general health, the specific disease or disorder involved, the degree of involvement or severity of the disease or disorder, the response of the individual, the specific incretin analog administered, the mode of administration, the bioavailability characteristics of the administered formulation, the selected dosing regimen, the use of concomitant drug therapy, and other relevant circumstances.
[0048] As used herein, "extended duration of action" refers to the duration of binding affinity and activity of incretin analogs that is greater than native human GIP, GLP-1, and GCG to allow for at least as low frequency dosing as once daily or even three times a week, twice a week, or once a week. The time action profile of incretin analogs can be measured using known pharmacokinetic assays, such as those used in the Examples below.
[0049] As used herein, "glucose-dependent insulinotropic polypeptide" or "GIP" refers to a 42-amino acid peptide (SEQ ID NO: 1) that is an incretin that plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells in the presence of glucose.
[0050] As used herein, "glucagon-like peptide-1" or "GLP-1" refers to a 36-amino acid peptide (SEQ ID NO: 2) that is also an incretin, stimulates glucose-dependent insulin secretion and has been shown to prevent hyperglycemia in diabetic patients.
[0051] As used herein, "glucagon" or "GCG" refers to a 29-amino acid peptide (SEQ ID NO: 3) that helps maintain blood sugar by binding to the GCG receptor on liver cells and activating it, causing the liver to release glucose stored in the form of glycogen through a process called glycogenolysis.
[0052] As used herein, "oxyntomodulin" or "OXM" refers to a 37-amino acid peptide (SEQ ID NO: 4) that includes not only the 29-amino acid sequence of GCG but also an octapeptide carboxyl-terminal extension that activates both GCG and GLP-1 receptors, with a slightly higher potency for the GCG receptor than the GLP-1 receptor.
[0053] As used herein, “half maximal effect concentration” or “EC 50 ” refers to the concentration of compound that results in 50% activation / stimulation of an assay endpoint such as a dose response curve (e.g. cAMP).
[0054] As used herein, "incretin analogs" refer to compounds that have structural similarities but also many differences with each of GIP, GLP-1 and GCG, especially human GIP (SEQ ID NO: 1), human GLP-1 (SEQ ID NO: 2) and human GCG (SEQ ID NO: 3). Incretin analogs herein include amino acid sequences that cause the compound to have affinity and activity (i.e., triple receptor agonist activity) for each of the GIP, GLP-1 and GCG receptors.
[0055] As used herein, "a subject in need thereof" refers to a mammal, such as a human, having a condition, disease, disorder or symptom requiring treatment or therapy, including, for example, those listed herein. In particular, the preferred subject to be treated is a human.
[0056] As used herein, "long-acting" means that the binding affinity and duration of activity of the incretin analogs herein are greater than that of a reference peptide, such as native human GIP (SEQ ID NO: 1), human GLP-1 (SEQ ID NO: 2) and / or human GCG (SEQ ID NO: 3), to allow for at least low frequency dosing such as once daily, three times a week, twice a week, once a week, or even once a month. The time profile of the incretin analogs herein can be measured using known pharmacokinetic methods, such as those described in the Examples below.
[0057] As used herein, "non-standard amino acids" refer to amino acids that may be naturally present in cells but are not involved in peptide synthesis. Non-standard amino acids may be components of peptides and may be generated by modifying standard amino acids in peptides (i.e., by post-translational modifications). Non-standard amino acids may include D-amino acids, which have the opposite absolute chirality of the above-mentioned standard L-amino acids.
[0058] As used herein, "saturated" refers to fatty acid moieties that do not contain carbon-carbon double or triple bonds.
[0059] As used herein, "treat," "treat," "treat," and the like refers to inhibiting, slowing, halting, or reversing the progression or severity of an existing condition, disease, disorder, or symptom.
[0060] As used herein and with respect to incretin mimetics, "triple receptor agonist activity" refers to incretin mimetics that have activity at each of the GIP, GLP-1, and GCG receptors, and in particular, incretin mimetics that have balanced and sufficient activity at each receptor to provide an agonist benefit of that receptor while avoiding undesirable side effects associated with too high an activity at that receptor. In addition, incretin mimetics with triple receptor agonist activity have a prolonged duration of action at each of the GIP, GLP-1, and GCG receptors, which advantageously allows for low-frequency dosing such as once daily, three times a week, twice a week, or once a week.
[0061] Certain abbreviations are defined as follows: “4Pal” means 3-(4-pyridyl)-L-alanine; “ACR” means urine albumin / urine creatinine ratio; “Aib” means α-aminoisobutyric acid; “αMeL” means α-methylleucine; “αMeK” means α-methyllysine; “αMeF” means α-methylphenylalanine; “αMeF(2F)” means α-methyl 2-fluorophenylalanine; “αMeY” means α-methyltyrosine; “amu” means atomic mass unit; “AUC” means area under the curve; “Boc” means tert-butyloxycarbonyl; “cAMP” means cyclic adenosine monophosphate; “DMSO” means dimethyl sulfoxide; “EIA / RIA” means enzyme immunoassay / radioimmunoassay; “Fmoc” means fluorenylmethoxycarbonyl; “hr ” means hours; “HTRF” means homogeneous time-resolved fluorescence; “IV” means intravenous; “Iva” means isovaline; “kDa” means kilodaltons; “LC-MS” means liquid chromatography-mass spectrometry; “min” means minutes; “MS” means mass spectrometry; “Orn” or “O” means ornithine; “OtBu” means O-tert-butyl; “Pbf” means NG-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; “RP-HPLC” means reversed-phase high performance liquid chromatography; “sec” means seconds; “SEM” means standard error of the mean; “SPA” means scintillation proximity analysis; “SQ” means subcutaneous; “TFA” means trifluoroacetic acid; “tBu” means tert-butyl; and “Trt” means trityl.
[0062] Incretin analogs
[0063] The structural features of the incretin analogs herein result in compounds that have sufficient activity at each of the GIP, GLP-1 and GCG receptors to obtain the beneficial effects of activity at each receptor (i.e., triple receptor agonist activity), but without the activity at any one receptor being so high as to overwhelm the activity at the other two receptors or without causing undesirable side effects when administered at doses sufficient to produce activity at all three receptors. In certain embodiments and with respect to SEQ ID NO: 5, non-limiting examples of such structural features include αMeF (2F) at position 6, which contributes to optimal GCG, GIP and GLP-1 activity; Y or 4Pal at position 10, which contributes to balanced activity; L or αMeL at position 13, which contributes to optimal GCG and GIP activity; O at position 16, which contributes to balanced activity; acylation at position 17, which contributes to balanced activity; 4Pal, Iva or αMeL at position 20, which contributes to optimal GCG activity; A or Aib at position 21, which contributes to optimal GCG activity; Y or αMeY at position 25, which contributes to balanced activity. Other examples of these structural features include amino acids described herein at positions 28-39, which contribute to optimal binding and potency at all three receptors.
[0064] The structural features of the incretin analogs herein also result in analogs having a number of other beneficial attributes relevant to their developability as therapeutic treatments, including improved solubility of the analogs in aqueous solutions, improved chemical and physical formulation stability, prolonged pharmacokinetic profiles, and minimized immunogenic potential. Non-limiting examples of specific structural features that confer these attributes include replacement of the incretin analogs with a C at position 17. 20 Fatty acid acylation, which contributes to optimal pharmacokinetic (PK) profile and developability; 4Pal at position 10 or 20, which contributes to optimal solubility and chemical stability; O at position 16, which contributes to optimal solubility and PK; E or e at position 24, which contributes to optimal solubility and stability; Y or αMeY at position 25, which contributes to optimal chemical stability; and E or S at position 39, which contributes to optimal solubility; and amino acids described herein at positions 6, 13, 16, and 28-39, which contribute to optimal PK, immunogenicity, developability, and stability.
[0065] It should be noted that the above enumeration of structural features is exemplary rather than comprehensive, and the combination of beneficial features of the exemplary analogs described herein is not the result of any modification alone, but is achieved by the novel combination of structural features described herein. In addition, the above effects of the above listed modifications are not exclusive, as many of these modifications also have other effects that are important to the characteristics of the compounds described herein as described below.
[0066] The amino acid sequences of the incretin analogs herein include naturally occurring (standard) amino acids generally depicted herein using single-letter codes (e.g., L = Leucine; K = Lysine), as well as non-standard amino acids and / or α-methyl substituted residues of standard amino acids (e.g., αMeL, αMeK, αMeF, αMeF(2F), and αMeY, and certain other non-standard amino acids, such as 4Pal, Aib, Iva, O, and D-Glutamic acid (e). For clarity, the structures of these other amino acids are depicted below:
[0067]
[0068]
[0069] .
[0070] As described above, the incretin analogs herein have structural similarities to any natural human peptide but also have many structural differences. For example, compared to natural human GIP (SEQ ID NO: 1), the incretin analogs include modifications at one or more of positions 2-3, 6-7, 13-14, 16-18, 20-21, 23-25 and 28-42. In some cases, the incretin analogs include modifications to the amino acids of natural human GIP (SEQ ID NO: 1) at each of positions 2-3, 6-7, 13-14, 16-18, 20-21, 23-25 and 28-42. In some cases, the incretin analogs include the following amino acid modifications: Aib at position 2; Q at position 3; αMeF (2F) at position 6; T at position 7; Y or 4Pal at position 10; L or αMeL at position 13; L at position 14; a modified K residue at position 17, which is replaced with C 16 To C 22The fatty acid is modified by conjugation to the ε-amino group of the K side chain, optionally by using a linker; A at position 18; 4Pal, Iva or αMeL at position 20; A or Aib at position 21; I at position 23; E or e at position 24; Y or αMeY at position 25; E at position 28; G at position 29; and replacing the amino acids at positions 30-42 with the following amino acid sequence: GPSSGAPPPE (SEQ ID NO: 12) or GPSSGAPPPS (SEQ ID NO: 13) (and truncated analogs of either of these tails). In other cases, the incretin analog is amidated. In addition to the modifications described herein, the incretin analog may also include one or more additional amino acid modifications, such as additions, deletions, insertions and / or substitutions, but remain capable of binding to and activating each of the GIP, GLP-1 and GCG receptors.
[0071] As described above, the incretin analogs herein include a fatty acid moiety conjugated to a standard or non-standard amino acid having a functional group available for conjugation, for example, via a linker. Such conjugation is sometimes referred to as acylation. In some cases, the amino acid having a functional group available for conjugation can be C, D, E, K, or Q. In specific cases, the amino acid having a functional group available for conjugation is K, wherein the conjugation is to the ε-amino group of the K side chain.
[0072] The incretin analogs described herein are acylated at position 17 in SEQ ID NO: 5, which was determined to be the optimal position for incorporation into this structure. The fatty acid moiety, and in some cases the linker, acts as an albumin binder and provides the potential to generate long-acting compounds.
[0073] The incretin analogs herein utilize C-terminal oligonucleotides conjugated to the functional groups of amino acids either by direct bonds or by linker chemistry. 16 -C 22 Fatty acid moiety. The length and composition of the fatty acid moiety affect the half-life of the incretin analog, the potency of the incretin analog in in vivo animal models, and the solubility and stability of the incretin analog. Conjugation to C 16 -C 22 The invention relates to producing incretin analogs on saturated fatty mono- or di-acids that exhibit desirable half-life, desirable potency in in vivo animal models, and desirable solubility and stability characteristics.
[0074] The saturated C 16 -C 22 Examples of fatty acids include, but are not limited to, palmitic acid (hexadecanoic acid) (C 16 monoacid), hexadecanedioic acid (C 16 diacid), pearlic acid (margaric acid) (heptadecanoic acid) (C17 monoacid), heptadecanedioic acid (C 17 Diacid), stearic acid (C 18 monoacid), octadecane dioic acid (C 18 diacid), nonadecanoic acid (nonadecanoic acid) (C 19 monoacid), nonadecanedioic acid (C 19 Diacid), arachidic acid (eicosanoic acid) (C 20 monoacid), eicosanedioic acid (C 20 dicarboxylic acid), eicosanoic acid (eicosanoic acid) (C 21 monoacid), heneicosane dioic acid (C 21 dicarboxylic acid), behenic acid (behenic acid) (C 22 monoacid), docosanoic acid (C 22 diacids), including their branched and substituted derivatives.
[0075] In some cases, C 16 -C 22 Fatty acids can be saturated 20 Monoacid, saturated C 20 Diacids and branched and substituted derivatives thereof. In a more particular case, C 16 -C 22 The fatty acid may be eicosanedioic acid.
[0076] In some cases, the linker can have 1 to 4 amino acids, aminopolyethylene glycol carboxylic acids, or mixtures thereof. In some cases, the aminopolyethylene glycol carboxylic acid has the following structure:
[0077]
[0078] wherein m is any integer from 1 to 12, n is any integer from 1 to 12, and p is 1 or 2.
[0079] In certain cases, the linker may have one or more AEEA moieties, optionally in combination with 1 to 4 amino acids.
[0080] In the case where the linker includes at least one amino acid, the amino acid may be 1 to 4 E or γE amino acid residues. In some cases, the linker may include one or two E or γE amino acid residues, including their D forms. For example, the linker may include one or two γE amino acid residues. Alternatively, the linker may include 1 to 4 amino acid residues (e.g., E or γE amino acids) used in combination with up to 36 AEEA moieties. Specifically, the linker may be a combination of 1 to 4 E or γE amino acids and 1 to 4 AEEA moieties. In other cases, the linker may be a combination of one or two γE amino acids and one or two AEEA moieties.
[0081] In one embodiment, the incretin analogs herein contain a linker-fatty acid moiety having the following structure:
[0082] ((2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γE) b -CO-(CH2) c -CO2H,
[0083] Wherein a is 0, 1 or 2, b is 1 or 2, and c is 16 or 18. In a specific case, a is 1, b is 1, and c is 20, which has the following structure:
[0084] .
[0085] As shown in the chemical structures of Examples 1-3 below, the above-mentioned linker-fatty acid moiety can be attached to the epsilon (ε)-amino group of the K side chain.
[0086] The affinity of the incretin analogs herein for each of the GIP, GLP-1, and GCG receptors can be measured using techniques known in the art for measuring receptor binding levels, including, for example, those described in the Examples below, and is typically expressed as an inhibition constant (Ki) value. The activity of the incretin analogs at each receptor can also be measured using techniques known in the art, including, for example, the in vitro activity assays described below, and is typically expressed as an effective concentration 50 (EC 50 ) value, which is the compound concentration that causes a half-maximal simulation in the dose-response curve.
[0087] The incretin analogs herein can be formulated as pharmaceutical compositions that can be administered parenterally (e.g., subcutaneously, intravenously, intraperitoneally, intramuscularly, or transdermally). Such pharmaceutical compositions and techniques for their preparation are well known in the art. See, for example, Remington: The Science and Practice of Pharmacy (Troy, Ed., 21st edition, Lippincott, Williams & Wilkins, 2006). In certain cases, the incretin analogs are administered subcutaneously.
[0088] The incretin analogs herein can react with any of several inorganic and organic acids / bases to form pharmaceutically acceptable acid / base addition salts. Pharmaceutically acceptable salts and common preparation techniques thereof are well known in the art (see, e.g., Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection and Use, 2nd Revised Edition (Wiley-VCH, 2011)). Pharmaceutically acceptable salts used herein include, but are not limited to, sodium salts, trifluoroacetates, hydrochlorides, and acetates.
[0089] The present disclosure also provides and therefore includes novel intermediates and methods for synthesizing the incretin analogs herein or pharmaceutically acceptable salts thereof. The intermediates and incretin analogs herein can be prepared by various techniques known in the art. For example, methods using chemical synthesis are illustrated in the following examples. The specific synthetic steps of each of the routes described can be combined in different ways to prepare the incretin analogs herein. Reagents and raw materials are readily available to those skilled in the art.
[0090] Certain incretin analogs herein are generally effective over a wide dosage range. For example, a dosage for once-weekly administration may fall within the range of about 0.01 to about 30 mg / individual / week, within the range of about 0.1 to about 10 mg / individual / week, or even within the range of about 0.1 to about 3 mg / individual / week. Thus, the incretin analogs herein may be administered daily, three times a week, twice a week, or once a week, particularly once a week.
[0091] The incretin analogs herein can be used to treat various conditions, disorders, diseases or symptoms. In particular, methods of treating T2DM in an individual are provided, wherein such methods include at least the step of administering to an individual in need of such treatment an effective amount of an incretin analog herein or a pharmaceutically acceptable salt thereof.
[0092] Additionally, methods of treating dyslipidemia in an individual are provided, wherein such methods comprise at least the step of administering to the individual in need of such treatment an effective amount of an incretin analog herein or a pharmaceutically acceptable salt thereof.
[0093] Additionally, provided are methods of treating metabolic syndrome in an individual, wherein such methods comprise at least the step of administering to the individual in need of such treatment an effective amount of an incretin analog herein or a pharmaceutically acceptable salt thereof.
[0094] Additionally, methods of treating NAFLD in an individual are provided, wherein such methods comprise at least the step of administering to the individual in need of such treatment an effective amount of an incretin analog herein or a pharmaceutically acceptable salt thereof.
[0095] Additionally, methods of treating NASH in an individual are provided, wherein such methods comprise at least the step of administering to an individual in need of such treatment an effective amount of an incretin analog herein, or a pharmaceutically acceptable salt thereof.
[0096] Additionally, methods of treating obesity in an individual are provided, wherein such methods comprise at least the step of administering to the individual in need of such treatment an effective amount of an incretin analog herein or a pharmaceutically acceptable salt thereof.
[0097] Additionally, methods of inducing non-therapeutic weight loss in an individual are provided, wherein such methods comprise at least the step of administering to an individual in need of such treatment an effective amount of an incretin analog herein or a pharmaceutically acceptable salt thereof.
[0098] Additionally, methods of treating cardiovascular disease that is not considered a metabolic disease are provided, wherein such methods comprise at least the step of administering to a subject in need of such treatment an effective amount of an incretin analog herein or a pharmaceutically acceptable salt thereof.
[0099] Additionally, methods of treating neurodegenerative diseases are provided, wherein such methods comprise at least the step of administering to a subject in need of such treatment an effective amount of an incretin analog herein or a pharmaceutically acceptable salt thereof.
[0100] In these methods, the effectiveness of the incretin analogs herein can be assessed by, for example, observing a significant decrease in blood glucose, observing a significant increase in insulin, observing a significant decrease in HbA1c, observing a significant decrease in blood lipids, observing a significant decrease in body weight or body fat, and / or observing changes in body composition.
[0101] Alternatively, the incretin analogs herein or pharmaceutically acceptable salts thereof may be used to improve bone strength in an individual in need thereof. In some cases, the individual in need thereof has hypoostosis or hypoosteoidosis, or is healing from a fracture, orthopedic surgery, prosthetic implant, dental implant, and / or spinal fusion. Incretin analogs may also be used to treat other disorders, such as Alzheimer's disease or Parkinson's disease. Example
[0102] The following non-limiting examples are offered for purposes of illustration and not limitation.
[0103] Peptide synthesis
[0104] Example 1: Synthesis of Incretin Analog 1
[0105] Example 1 is a compound represented by the following description:
[0106] YAibQGT-αMeF(2F)-TSDYSILLDOK(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl-γE-CO-(CH2) 18 -CO2H)AQ-4Pal-AFIEYLLEGGPSSGEPPPE-NH2 (SEQ ID NO:9).
[0107] The structure of Example 1 is depicted below using the standard single letter amino acid code except for residues Aib2, αMeF(2F)6, O16, K17, 4Pal20, and E39, in which the structures of these amino acid residues have been expanded:
[0108]
[0109] The peptide backbone of Example 1 was synthesized using Fmoc / t-Bu chemistry on a Symphony X peptide synthesizer (Gyros Protein Technologies; Tucson, AZ).
[0110] The resin was 1% DVB cross-linked polystyrene at a degree of substitution of 0.3-0.4 meq / g (Fmoc-Rink-MBHA low loading resin, 100-200 mesh; EMD Millipore). Standard side chain protecting groups were used with the following exceptions. Fmoc-Lys(Mtt)-OH was used for K at position 17, Boc-Tyr(tBu)-OH) was used for Y at position 1. The Fmoc group was removed using 20% piperidine / DMF before each coupling step (2 x 7 min). All standard amino acid couplings were performed using equimolar ratios of Fmoc amino acids (0.3 mM), diisopropylcarbodiimide (0.9 mM), and Oxyma (0.9 mM) at a 9-fold molar excess relative to theoretical peptide loading for 1 h (coupling to primary amines) and 3 h (coupling to secondary amines). The exception was coupling to Cα-methylated amino acids, which were coupled for 3 h. After completion of peptide backbone synthesis, the resin was washed extensively 6 times with DCM to remove residual DMF. The Mtt protecting group at K in position 17 was selectively removed from the peptide resin using two treatments (2 x 40 min treatments) of 30% hexafluoroisopropanol (Oakwood Chemicals) / DCM.
[0111] Subsequent attachment of the fatty acid-linker moiety was achieved by coupling of 2-[2-(2-Fmoc-amino-ethoxy)-ethoxy]-acetic acid (Fmoc-AEEA-OH, ChemPep, Inc.), Fmoc-glutamic acid α-t-butyl ester (Fmoc-E-OtBu, Ark Pharm, Inc.), and mono-OtBu-eicosanoic acid (WuXi AppTec, Shanghai, China). A 3-fold excess of reagents (AA: PyAOP: DIPEA = 1: 1: 1 mol / mol) was used for each coupling for 1 h.
[0112] After the synthesis was complete, the peptide resin was washed with DCM and then air-dried thoroughly. The dried resin was treated with 10 ml of cleavage cocktail (TFA: triisopropylsilane: water, 92.5:2.5:5 volume ratio) at 40°C for 30 minutes. The resin was filtered off, washed twice with 2 ml of pure TFA each, and the combined filtrates were treated with a 5-fold excess volume of cold ether (-20°C) to precipitate the crude peptide. The peptide / ether suspension was then centrifuged at 3500 rpm for 2 minutes to form a solid pellet, the supernatant was decanted, and the solid pellet was triturated with cold ether twice more and dried in vacuo. The crude peptide was dissolved in 20% acetonitrile / 20% acetic acid / 60% water and purified by RP-HPLC with a linear gradient (30-50% acetonitrile in 60 min) of 100% acetonitrile and 0.1% TFA / water buffer system on a Luna 5 µm phenyl-hexyl preparative column (21 x 250 mm; Phenomenex). The purity of the peptide was assessed using analytical RP-HPLC and the pooling criteria was >95%. The main pool purity of Example 1 was found to be >98.0%. Subsequent lyophilization of the final main product pool produced a lyophilized peptide TFA salt. The molecular weight was determined by LC-MS (observed: M+3 =1633.7; calculated M+3 =1633.8).
[0113] Example 2: Synthesis of Incretin Analog 2
[0114] Example 2 is a compound represented by the following description:
[0115] YAibQGT-αMeF(2F)-TSDYSI-αMeL-LDOK(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl-γE-CO-(CH2) 18 -CO2H)AQ-Iva-AFIE-αMeY-LLEGGPSSGEPPPS-NH2 (SEQ ID NO: 10).
[0116] The structure of Example 2 is depicted below using the standard single letter amino acid code except for residues Aib2, αMeF(2F)6, αMeL13, O16, K17, Iva20, αMeY25, and S39, in which the structures of these amino acid residues have been expanded:
[0117]
[0118] The peptide backbone was synthesized, the fatty acid-linker moiety was conjugated, the purity was checked and the molecular weight of Example 2 was confirmed using methods similar to those described above for Example 1.
[0119] Example 3: Synthesis of Incretin Analog 3
[0120] Example 3 is a compound represented by the following description:
[0121] YAibQGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LDOK(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl-γE-CO-(CH2) 18 -CO2H)AQ-αMeL-Aib-FIe-αMeY-LLEGGPSSGEPPPS-NH2 (SEQ ID NO: 11).
[0122] The structure of Example 3 is depicted below using the standard single letter amino acid code except for residues Aib2, αMeF(2F)6, 4Pal10, αMeL13, O16, K17, αMeL20, Aib21, e24, αMeY25, and S39, in which the structures of these amino acid residues have been expanded:
[0123]
[0124] The peptide backbone was synthesized, the fatty acid-linker moiety was conjugated, the purity was checked and the molecular weight of Example 3 was confirmed using methods similar to those described above for Example 1.
[0125] In vitro function
[0126] Example 4: Binding Affinity
[0127] Radioligand competition binding assays were used to determine the equilibrium dissociation constants of example compounds and comparators. Such assays used the SPA method and membranes prepared from transfected HEK293 cells overexpressing human GIP receptor (hGIPR; SEQ ID NO: 14), human GLP-1 receptor (hGLP-1R; SEQ ID NO: 15), or human GCG receptor (hGCGR; SEQ ID NO: 16).
[0128] The assay was performed in the presence of bacitracin as a nonspecific blocking agent to prevent the binding of the acylated moieties of the tested analogs to protein components (e.g., albumin) used in standard assay buffers.
[0129] Competition curves were plotted as percent specific inhibition (y-axis) vs. logarithmic concentration of compound (x-axis) and analyzed using a four-parameter nonlinear regression fit (ABase or Genedata) with variable slope. i =IC 50 / (1+(D / K d Calculate K i Value, where IC 50 is the concentration of compound that results in 50% inhibition of binding, D is the concentration of radioligand used in the assay, and K d is the equilibrium dissociation constant for the receptor and the radioligand determined by saturation binding analysis (shown in Table 1 below).
[0130] Table 1: K determined by saturation binding assay d
[0131] .
[0132] K of Example Compounds and Comparative Compounds i The values are shown in Table 2.
[0133] Table 2: In vitro K of Example compounds and comparative substances for hGIPR, hGLP-1R and hGCGR i
[0134]
[0135] Note: The modifier (>) indicates that the data did not achieve 50% inhibition relative to maximal binding, thus the highest concentration tested in this assay was used to calculate K. i n = 1 / x means that only one value out of the total number of replicates (x) is used to express the mean. The SEM is calculated only when there are n = 2 or more unqualified results.
[0136] As seen in Table 2, the Example compounds have binding affinity at each of hGIPR, hGLP-1R and hGCGR.
[0137] Example 5: Functional hGIPR, hGLP-1R and hGCGR Assays
[0138] Methods: Functional activity was determined using cAMP formation in HEK-293 clonal cell lines expressing hGIPR, hGLP-1R, or hGCGR. In a 20 µL assay volume (final DMSO concentration of 0.5%), 1X GlutaMAX TM Cells expressing hGIPR, hGLP-1R or hGCGR receptor were treated with control polypeptide or one of Examples 1 to 3 (20 point concentration-response curve in DMSO, 2.75-fold Labcyte Echo direct dilution, 384-well plate Corning Cat# 3570) in DMEM (Gibco Cat# 31053) containing 1% bovine casein (Sigma C4765-10ML), 250 µM IBMX (3-isobutyl-1-methylxanthine, Acros Cat# 228420010) and 20 mM HEPES (Gibco Cat# 15630). Experiments were also performed under the same assay conditions with the addition of 1.0% fatty acid-free, globulin-free human serum albumin (Sigma Cat# A3782).
[0139] After incubation at 37°C for 30 min, the resulting increase in intracellular cAMP was quantified using the CisBio cAMP Dynamic 2 HTRF Assay Kit (62AM4PEJ). Briefly, the cells were lysed by adding cAMP-d2 conjugate in cell lysis buffer (10 µL), followed by the addition of the antibody anti-cAMP-Eu in cell lysis buffer (10 µL). 3+ -cryptate, to detect intracellular cAMP levels. The resulting competition assay was incubated at room temperature for at least 60 minutes and then detected using a PerkinElmer Envision® instrument at excitation at 320 nm and emission at 665 nm and 620 nm. Envision units (emission at 665nm / 620nm*10,000) are inversely proportional to the amount of cAMP present and are converted to nM cAMP per well using a cAMP standard curve. The amount of cAMP generated in each well (nM) was converted to a percentage of the maximal response observed with human GIP(1-42)NH2, hGLP-1(7-36)NH2, or hGCG. Relative EC values were derived by nonlinear regression analysis using the percentage of maximal response vs. the concentration of peptide added. 50 Value and % top (E max ), fitted to a four-parameter logarithmic equation.
[0140] Results: Functional data for hGIP(1-42)NH2, hGLP-1(7-36)NH2, hGCG and Example compounds are provided below in Table 3 (0.1% bovine casein) and Table 4 (0.1% bovine casein, 1.0% human serum albumin).
[0141] Table 3: Functional cAMP potency (EC) of peptides incubated at 37°C (in the presence of 0.1% bovine casein) 50 ) and efficacy (E max )
[0142]
[0143] Note: a use[ 125 I] GLP-1(7-36)NH2 at hGLP-1R (112 fmol / mg protein), [ 125 I]GCG at hGCGR (98 fmol / mg protein) and [ 125 I] Homologous competition binding assay of GIP(1-42) expression density at hGIPR (124 fmol / mg protein). b EC 50 , nM = geometric mean with standard error of the mean followed by the number of observations in parentheses. c E max , % = arithmetic mean of the percentage of maximal response to GLP-1(7-36)NH2 at hGLP-1R, GCG at hGCGR, or GIP(1-42)NH2 at hGIPR ± standard error of the mean. All values are presented to three (3) significant digits.
[0144] Table 4: Functional cAMP potency (EC) of peptides incubated at 37°C in the presence of 0.1% bovine casein and 1.0% human serum albumin. 50 ) and efficacy (E max )
[0145]
[0146] Note: a use[ 125 I] GLP-1(7-36)NH2 at hGLP-1R (112 fmol / mg protein), [ 125 I]GCG at hGCGR (98 fmol / mg protein) and [ 125 I] Homologous competition binding assay of GIP(1-42) expression density at hGIPR (124 fmol / mg protein). b EC50 , nM = geometric mean with standard error of the mean followed by the number of observations in parentheses. c E max , % = arithmetic mean of the percentage of maximal response to GLP-1(7-36)NH2 at hGLP-1R, GCG at hGCGR, or GIP(1-42)NH2 at hGIPR ± standard error of the mean. All values are presented to three (3) significant digits.
[0147] As seen in Table 3, in the presence of 0.1% casein, the Example compounds stimulated cAMP from hGLP-1R, hGCGR, and hGIPR.
[0148] As seen in Table 4, in the presence of 0.1% bovine casein and 1% human serum albumin, the Example compounds stimulated cAMP from hGLP-1R, hGCGR, and hGIPR.
[0149] Function in the body
[0150] Example 6: Pharmacokinetics in Male Diet-Induced Obese (DIO) Mice
[0151] Methods: A single SQ dose of 200 nmol / kg (0.98 mg / kg) of Example Compound in 40 mM Tris-HCL pH 8 buffer containing 0.02% PS80 was administered to male DIO mice in a volume of 10 mL / kg. Blood was collected at 1, 3, 6, 12, 24, 48, and 72 hours after dosing for pharmacokinetic characterization. Plasma concentrations of Example Compound were determined by qualified liquid chromatography mass spectrometry (LC / MS) at Q Squared Solutions BioSciences LLC (Ithaca, NY). Example Compound and internal standard were extracted from 100% mouse plasma using protein precipitation followed by solid phase extraction. The intact mass of Example Compound including peptide and acyl chains was detected by Q-Exactive™ Orbitrap® mass spectrometer.
[0152] Results: The data for the example compounds are provided in Table 5 below.
[0153] Table 5: Mean plasma pharmacokinetic parameters following a single 200 nmol / kg subcutaneous dose in male DIO mice
[0154]
[0155] Note: Abbreviation: t 1 / 2 = half-life, T max = time to reach maximum concentration, Cmax = Maximum observed plasma concentration, AUC 0-inf = area under the curve from time 0 hours to infinity, CL / F = clearance / bioavailability. N = 3 animals / group / time point.
[0156] As seen in Table 5, the Example compounds exhibited a prolonged pharmacokinetic profile in DIO mice.
[0157] Example 7: In vivo effects on insulin secretion in male Wistar rats
[0158] Methods: Insulinotropic effects of Example compounds were evaluated using an intravenous glucose tolerance test (ivGTT) in male Wistar rats. The GLP-1R agonist semaglutide was used as a positive control. Rats with surgically cannulated jugular veins and carotid arteries were housed one per cage in polycarbonate cages with a filtered air dome (Envigo; Indianapolis, IN, 280-320 g). Rats were maintained on a 12-h light-dark cycle at 21°C and had ad libitum access to 2014 Teklad Global diet (Envigo) and deionized water. Rats were randomized by body weight and given 1.5 mL / kg of Example compounds subcutaneously 16 hours before glucose administration and then fasted. Example compounds at a stock concentration of 211 nM / mL were diluted to the desired dosing concentrations in 40 mM Tris-HCl buffer pH 8.0 containing 0.02% PS80; doses tested were vehicle, 0.1, 0.3, 1, 3, 10, and 30 nM / kg. Semaglutide was used as a positive control in conjunction with each run of Example compounds (10 nM / kg dose).
[0159] Blood samples were collected into EDTA tubes at time 0, after which glucose (0.5 mg / kg, 5 mL / kg) was administered. Blood samples were collected 2, 4, 6, 10, 20, and 30 minutes after intravenous glucose administration to determine glucose and insulin levels. Plasma insulin was determined using electrochemiluminescence analysis (Meso Scale; Rockville, MD). Insulin AUC was examined in comparison with vehicle control, n = 6 animals per group.
[0160] Statistical analysis was performed using JMP with one-way ANOVA followed by Dunnett's comparison to vehicle control.
[0161] Results: The data for the example compounds are provided in Table 6 below.
[0162] Table 6: Effects of vehicle, semaglutide (Sema, 10 nmol / kg) and example compounds on insulin secretion during ivGTT in Wistar rats
[0163]
[0164] Note: Results are expressed as mean ± standard error of mean (SEM) of 6 rats per group. Statistical test was one-way ANOVA followed by Dunnett's *p<0.05 compared with vehicle; +p<0.05 compared with semaglutide.
[0165] As seen in Table 6, the Example compounds dose-dependently increased insulin secretion.
[0166] Example 8: In vivo studies of weight loss, metabolism and body composition in DIO C57 / B16 mice
[0167] Methods: To investigate the effects of Example compounds on parameters such as weight loss, metabolism and body composition, Example compounds were administered to C57B16 DIO mice. After 20 weeks of being placed on a high fat diet, these animals, although not diabetic, exhibited insulin resistance and dyslipidemia, which are features of metabolic syndrome.
[0168] Here, 20-week-old DIO male C57 / Bl6 mice on a high-calorie diet were used in the following studies. Animals were housed individually in a temperature-controlled (23°C to 26°C) facility with a 12-h light-dark cycle (lights on at 21:00) and had ad libitum access to food (TD95217) and water. After 3 weeks of acclimation to the facility (including 1 week of vehicle acclimation dosing), mice were randomized according to their body weight so that animals in each experimental group had similar body weights. Body weights ranged from 40 g to 51 g.
[0169] All groups contained 6 mice. Example compounds and semaglutide were dissolved in vehicle (40 mM Tris-HCl, pH 8.0, containing 0.02% PS-80) and administered to ad libitum DIO mice by SQ injection (10 mL / kg) 30 to 120 minutes before the onset of the dark cycle every day for 14 days (Days 1 to 14). Body weight and food intake were measured daily throughout the study, including 1 day after the last dose (Day 15).
[0170] The absolute change in body weight was calculated by subtracting the body weight of the same animal before the first injection of the molecule. Total fat mass was measured on days 0 and 15 by nuclear magnetic resonance (NMR) using an Echo Medical System (Houston, TX) instrument. Metabolic parameters were measured on day 15 using an Accu-Chek® Aviva® glucometer (Roche; Indianapolis, IN) or a Hitachi clinical hematology analyzer (Roche, Indianapolis, IN). Plasma insulin was measured using an electrochemiluminescence assay (Meso ScaleDiscovery, Rockville, MD).
[0171] Data are shown in Tables 7 and 8 below as mean ± SEM of 6 animals per group. Statistical analysis was performed using repeated measures ANOVA followed by Dunnett's method for multiple comparisons. Significant differences of p<0.05 were considered *.
[0172] Results: The data for the example compounds are provided in Tables 7 and 8 below.
[0173] Table 7. Changes in body weight after 15 days of treatment with semaglutide and example compounds
[0174]
[0175] Note: "Δ Body Weight (g)" refers to the difference in body weight between the experimental group and the vehicle group on day 15. "Δ Body Weight (%)" refers to the percentage of body weight loss between day 1 and day 15 in the experimental group. "Fat Mass (%)" refers to the difference in fat mass between day 0 and day 15 in the experimental group. "Sema" refers to Semaglutide. All data are from a single representative study. The percent change in body weight and fat mass of animals receiving vehicle was recorded and was less than 2% in each study. For Semaglutide and all Examples, "Δ Body Weight (g)", "Δ Body Weight (%)" and "Δ Fat Mass (%)" were statistically significantly different (*, p<0.05) from the control at all doses tested, except for the Example peptide at a low dose of 0.15625 nmol / kg.
[0176] As seen in Table 7, the Example compounds dose-dependently reduced body weight and fat mass.
[0177] Table 8: Effects of treatment with example compounds on blood glucose, insulin, total cholesterol and triglycerides after 15 days
[0178]
[0179] Note: All data refer to the difference between the experimental group and the vehicle group at day 15 and are from a single representative study. "Sema" refers to semaglutide. *p<0.05 compared with the vehicle group; one-way ANOVA, Dunnett's.
[0180] As seen in Table 8, the Example compounds also lowered blood glucose, insulin (as a marker of improved insulin sensitivity), cholesterol and triglycerides.
[0181] Sequence Listing
[0182] The following nucleic acid and / or amino acid sequences are mentioned in the above disclosure and are provided below for reference.
[0183] SEQ ID NO: 1 - Human GIP
[0184]
[0185] SEQ ID NO:2 – Human GLP-1 7-36 Amide
[0186]
[0187] SEQ ID NO:3 - Human Glucagon
[0188]
[0189] SEQ ID NO:4 - Human OXM
[0190]
[0191] SEQ ID NO:5 - Incretin analog
[0192]
[0193] in:
[0194] X2 is Aib,
[0195] X6 is αMeF(2F),
[0196] X 10 It can be Y or 4Pal,
[0197] X 13 Can be L or αMeL,
[0198] X 16 It's Orn,
[0199] X 17 is any amino acid having a functional group available for conjugation,
[0200] X 20 It can be 4Pal, Iva or αMeL,
[0201] X 21 Can be A or Aib,
[0202] X 24 It can be E or e,
[0203] X 25 can be Y or αMeY, and
[0204] X 39 Can be E or S
[0205] SEQ ID NO:6 - Incretin analog
[0206]
[0207] SEQ ID NO:7 - Incretin analog
[0208]
[0209] SEQ ID NO:8 - Incretin analog
[0210]
[0211] SEQ ID NO:9 - Incretin analog
[0212] Y-Aib-QGT-αMeF(2F)-TSDYSILLDOK(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl
[0213] SEQ ID NO: 10 - Incretin analog
[0214] Y-Aib-QGT-αMeF(2F)-TSDYSI-αMeL-LDOK(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl
[0215] SEQ ID NO:11 - Incretin analog
[0216] Y-Aib-QGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LDOK(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl
[0217] SEQ ID NO:12 – Artificial sequence
[0218]
[0219] SEQ ID NO:13 – Artificial sequence
[0220]
[0221] SEQ ID NO:14 - Human GIP receptor
[0222]
[0223] SEQ ID NO: 15 - Human GLP-1 receptor
[0224]
[0225] SEQ ID NO:16 - Human GCG receptor
[0226] Sequence Listing <110> Eli Lilly and Company <120> Incretin analogs and their uses <130> P22622 <160> 16 <170> PatentIn version 3.5 <210> 1 <211> 42 <212> PRT <213> Homo sapiens <400> 1 Tyr Ala Glu Gly Thr Phe Ile Ser Asp Tyr Ser Ile Ala Met Asp Lys 1 5 10 15 Ile His Gln Gln Asp Phe Val Asn Trp Leu Leu Ala Gln Lys Gly Lys 20 25 30 Lys Asn Asp Trp Lys His Asn Ile Thr Gln 35 40 <210> 2 <211> 30 <212> PRT <213> Homo sapiens <220> <221> MOD_RES <222> (30)..(30) <223> Amidation <400> 2 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 20 25 30 <210> 3 <211> 29 <212> PRT <213> Homo sapiens <400> 3 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 4 <211> 37 <212> PRT <213> Homo sapiens <400> 4 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn 20 25 30 Arg Asn Asn Ile Ala 35 <210> 5 <211> 39 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is Aib <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is α-MeF(2F) <220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa at position 10 is Y or 4Pal <220> <221> MISC_FEATURE <222> (13) <223> Xaa at position 13 is L or α-MeL <220> <221> MISC_FEATURE <222> (16) <223> Xaa at position 16 is Orn <220> <221> MISC_FEATURE <222> (17) <223> Xaa at position 17 is any amino acid having a functional group available for conjugation <220> <221> MISC_FEATURE <222> (20)..(20) <223> Xaa at position 20 is 4Pal, Iva or α-MeL <220> <221> MISC_FEATURE <222> (21)..(21) <223> Xaa at position 21 is A or Aib <220> <221> MISC_FEATURE <222> (24)..(24) <223> Xaa at position 24 is E or D-Glu <220> <221> MISC_FEATURE <222> (25)..(25) <223> Xaa at position 25 is Y or α-MeY <220> <221> MISC_FEATURE <222> (39)..(39) <223> Xaa at position 39 is E or S <400> 5 Tyr Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Ile Xaa Leu Asp Xaa 1 5 10 15 Xaa Ala Gln Xaa Xaa Phe Ile Xaa Xaa Leu Leu Glu Gly Gly Pro Ser 20 25 30 Ser Gly Glu Pro Pro Pro Xaa 35 <210> 6 <211> 39 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is Aib <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is α-MeF(2F) <220> <221> MISC_FEATURE <222> (16) <223> Xaa at position 16 is Orn <220> <221> MISC_FEATURE <222> (20)..(20) <223> Xaa at position 20 is 4Pal <400> 6 Tyr Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Ile Leu Leu Asp Xaa 1 5 10 15 Lys Ala Gln Xaa Ala Phe Ile Glu Tyr Leu Leu Glu Gly Gly Pro Ser 20 25 30 Ser Gly Glu Pro Pro Pro Glu 35 <210> 7 <211> 39 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is Aib <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is α-MeF(2F) <220> <221> MISC_FEATURE <222> (13) <223> Xaa at position 13 is α-MeL <220> <221> MISC_FEATURE <222> (16) <223> Xaa at position 16 is Orn <220> <221> MISC_FEATURE <222> (20)..(20) <223> Xaa at position 20 is Iva <220> <221> MISC_FEATURE <222> (25)..(25) <223> Xaa at position 25 is α-MeY <400> 7 Tyr Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Ile Xaa Leu Asp Xaa 1 5 10 15 Lys Ala Gln Xaa Ala Phe Ile Glu Xaa Leu Leu Glu Gly Gly Pro Ser 20 25 30 Ser Gly Glu Pro Pro Pro Ser 35 <210> 8 <211> 39 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is Aib <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is α-MeF(2F) <220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa at position 10 is 4Pal <220> <221> MISC_FEATURE <222> (13) <223> Xaa at position 13 is α-MeL <220> <221> MISC_FEATURE <222> (16) <223> Xaa at position 16 is Orn <220> <221> MISC_FEATURE <222> (20)..(20) <223> Xaa at position 20 is α-MeL <220> <221> MISC_FEATURE <222> (21)..(21) <223> Xaa at position 21 is Aib <220> <221> MISC_FEATURE <222> (24)..(24) <223> Xaa at position 24 is D-Glu <220> <221> MISC_FEATURE <222> (25)..(25) <223> Xaa at position 25 is α-MeY <400> 8 Tyr Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Ile Xaa Leu Asp Xaa 1 5 10 15 Lys Ala Gln Xaa Xaa Phe Ile Xaa Xaa Leu Leu Glu Gly Gly Pro Ser 20 25 30 Ser Gly Glu Pro Pro Pro Ser 35 <210> 9 <211> 39 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is Aib <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is α-MeF(2F) <220> <221> MISC_FEATURE <222> (16) <223> Xaa at position 16 is Orn <220> <221> MOD_RES <222> (17) <223> K at position 17 was chemically modified by conjugation of the ε-amino group of the K side chain with (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)18-CO2H <220> <221> MISC_FEATURE <222> (20)..(20) <223> Xaa at position 20 is 4Pal <220> <221> MOD_RES <222> (39)..(39) <223> The glutamic acid at position 39 is amidated <400> 9 Tyr Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Ile Leu Leu Asp Xaa 1 5 10 15 Lys Ala Gln Xaa Ala Phe Ile Glu Tyr Leu Leu Glu Gly Gly Pro Ser 20 25 30 Ser Gly Glu Pro Pro Pro Glu 35 <210> 10 <211> 39 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is Aib <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is α-MeF(2F) <220> <221> MISC_FEATURE <222> (13) <223> Xaa at position 13 is α-MeL <220> <221> MISC_FEATURE <222> (16) <223> Xaa at position 16 is Orn <220> <221> MOD_RES <222> (17) <223> K at position 17 was chemically modified by conjugation of the ε-amino group of the K side chain with (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)18-CO2H <220> <221> MISC_FEATURE <222> (20)..(20) <223> Xaa at position 20 is Iva <220> <221> MISC_FEATURE <222> (25)..(25) <223> Xaa at position 25 is α-MeY <220> <221> MOD_RES <222> (39)..(39) <223> Ser at position 39 is amidated <400> 10 Tyr Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Ile Xaa Leu Asp Xaa 1 5 10 15 Lys Ala Gln Xaa Ala Phe Ile Glu Xaa Leu Leu Glu Gly Gly Pro Ser 20 25 30 Ser Gly Glu Pro Pro Pro Ser 35 <210> 11 <211> 39 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is Aib <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is αMeF(2F) <220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa at position 10 is 4Pal <220> <221> MISC_FEATURE <222> (13) <223> Xaa at position 13 is α-MeL <220> <221> MISC_FEATURE <222> (16) <223> Xaa at position 16 is Orn <220> <221> MOD_RES <222> (17) <223> K at position 17 was chemically modified by conjugation of the ε-amino group of the K side chain with (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)18-CO2H <220> <221> MISC_FEATURE <222> (20)..(20) <223> Xaa at position 20 is α-MeL <220> <221> MISC_FEATURE <222> (21)..(21) <223> Xaa at position 21 is Aib <220> <221> MISC_FEATURE <222> (24)..(24) <223> Xaa at position 24 is D-Glu <220> <221> MISC_FEATURE <222> (25)..(25) <223> Xaa at position 25 is α-MeY <220> <221> MISC_FEATURE <222> (39)..(39) <223> Ser at position 39 is amidated <400> 11 Tyr Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Ile Xaa Leu Asp Xaa 1 5 10 15 Lys Ala Gln Xaa Xaa Phe Ile Xaa Xaa Leu Leu Glu Gly Gly Pro Ser 20 25 30 Ser Gly Glu Pro Pro Pro Ser 35 <210> 12 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 12 Gly Pro Ser Ser Gly Glu Pro Pro Pro Glu 1 5 10 <210> 13 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 13 Gly Pro Ser Ser Gly Glu Pro Pro Pro Ser 1 5 10 <210> 14 <211> 466 <212> PRT <213> Homo sapiens <400> 14 Met Thr Thr Ser Pro Ile Leu Gln Leu Leu Leu Arg Leu Ser Leu Cys 1 5 10 15 Gly Leu Leu Leu Gln Arg Ala Glu Thr Gly Ser Lys Gly Gln Thr Ala 20 25 30 Gly Glu Leu Tyr Gln Arg Trp Glu Arg Tyr Arg Arg Glu Cys Gln Glu 35 40 45 Thr Leu Ala Ala Ala Glu Pro Pro Ser Gly Leu Ala Cys Asn Gly Ser 50 55 60 Phe Asp Met Tyr Val Cys Trp Asp Tyr Ala Ala Pro Asn Ala Thr Ala 65 70 75 80 Arg Ala Ser Cys Pro Trp Tyr Leu Pro Trp His His His Val Ala Ala 85 90 95 Gly Phe Val Leu Arg Gln Cys Gly Ser Asp Gly Gln Trp Gly Leu Trp 100 105 110 Arg Asp His Thr Gln Cys Glu Asn Pro Glu Lys Asn Glu Ala Phe Leu 115 120 125 Asp Gln Arg Leu Ile Leu Glu Arg Leu Gln Val Met Tyr Thr Val Gly 130 135 140 Tyr Ser Leu Ser Leu Ala Thr Leu Leu Leu Ala Leu Leu Ile Leu Ser 145 150 155 160 Leu Phe Arg Arg Leu His Cys Thr Arg Asn Tyr Ile His Ile Asn Leu 165 170 175 Phe Thr Ser Phe Met Leu Arg Ala Ala Ala Ile Leu Ser Arg Asp Arg 180 185 190 Leu Leu Pro Arg Pro Gly Pro Tyr Leu Gly Asp Gln Ala Leu Ala Leu 195 200 205 Trp Asn Gln Ala Leu Ala Ala Cys Arg Thr Ala Gln Ile Val Thr Gln 210 215 220 Tyr Cys Val Gly Ala Asn Tyr Thr Trp Leu Leu Val Glu Gly Val Tyr 225 230 235 240 Leu His Ser Leu Leu Val Leu Val Gly Gly Ser Glu Glu Gly His Phe 245 250 255 Arg Tyr Tyr Leu Leu Leu Gly Trp Gly Ala Pro Ala Leu Phe Val Ile 260 265 270 Pro Trp Val Ile Val Arg Tyr Leu Tyr Glu Asn Thr Gln Cys Trp Glu 275 280 285 Arg Asn Glu Val Lys Ala Ile Trp Trp Ile Ile Arg Thr Pro Ile Leu 290 295 300 Met Thr Ile Leu Ile Asn Phe Leu Ile Phe Ile Arg Ile Leu Gly Ile 305 310 315 320 Leu Leu Ser Lys Leu Arg Thr Arg Gln Met Arg Cys Arg Asp Tyr Arg 325 330 335 Leu Arg Leu Ala Arg Ser Thr Leu Thr Leu Val Pro Leu Leu Gly Val 340 345 350 His Glu Val Val Phe Ala Pro Val Thr Glu Glu Gln Ala Arg Gly Ala 355 360 365 Leu Arg Phe Ala Lys Leu Gly Phe Glu Ile Phe Leu Ser Ser Phe Gln 370 375 380 Gly Phe Leu Val Ser Val Leu Tyr Cys Phe Ile Asn Lys Glu Val Gln 385 390 395 400 Ser Glu Ile Arg Arg Gly Trp His His Cys Arg Leu Arg Arg Ser Leu 405 410 415 Gly Glu Glu Gln Arg Gln Leu Pro Glu Arg Ala Phe Arg Ala Leu Pro 420 425 430 Ser Gly Ser Gly Pro Gly Glu Val Pro Thr Ser Arg Gly Leu Ser Ser 435 440 445 Gly Thr Leu Pro Gly Pro Gly Asn Glu Ala Ser Arg Glu Leu Glu Ser 450 455 460 Tyr Cys 465 <210> 15 <211> 463 <212> PRT <213> Homo sapiens <400> 15 Met Ala Gly Ala Pro Gly Pro Leu Arg Leu Ala Leu Leu Leu Leu Gly 1 5 10 15 Met Val Gly Arg Ala Gly Pro Arg Pro Gln Gly Ala Thr Val Ser Leu 20 25 30 Trp Glu Thr Val Gln Lys Trp Arg Glu Tyr Arg Arg Gln Cys Gln Arg 35 40 45 Ser Leu Thr Glu Asp Pro Pro Pro Ala Thr Asp Leu Phe Cys Asn Arg 50 55 60 Thr Phe Asp Glu Tyr Ala Cys Trp Pro Asp Gly Glu Pro Gly Ser Phe 65 70 75 80 Val Asn Val Ser Cys Pro Trp Tyr Leu Pro Trp Ala Ser Ser Val Pro 85 90 95 Gln Gly His Val Tyr Arg Phe Cys Thr Ala Glu Gly Leu Trp Leu Gln 100 105 110 Lys Asp Asn Ser Ser Leu Pro Trp Arg Asp Leu Ser Glu Cys Glu Glu 115 120 125 Ser Lys Arg Gly Glu Arg Ser Ser Pro Glu Glu Gln Leu Leu Phe Leu 130 135 140 Tyr Ile Ile Tyr Thr Val Gly Tyr Ala Leu Ser Phe Ser Ala Leu Val 145 150 155 160 Ile Ala Ser Ala Ile Leu Leu Gly Phe Arg His Leu His Cys Thr Arg 165 170 175 Asn Tyr Ile His Leu Asn Leu Phe Ala Ser Phe Ile Leu Arg Ala Leu 180 185 190 Ser Val Phe Ile Lys Asp Ala Ala Leu Lys Trp Met Tyr Ser Thr Ala 195 200 205 Ala Gln Gln His Gln Trp Asp Gly Leu Leu Ser Tyr Gln Asp Ser Leu 210 215 220 Ser Cys Arg Leu Val Phe Leu Leu Met Gln Tyr Cys Val Ala Ala Asn 225 230 235 240 Tyr Tyr Trp Leu Leu Val Glu Gly Val Tyr Leu Tyr Thr Leu Leu Ala 245 250 255 Phe Ser Val Leu Ser Glu Gln Trp Ile Phe Arg Leu Tyr Val Ser Ile 260 265 270 Gly Trp Gly Val Pro Leu Leu Phe Val Val Pro Trp Gly Ile Val Lys 275 280 285 Tyr Leu Tyr Glu Asp Glu Gly Cys Trp Thr Arg Asn Ser Asn Met Asn 290 295 300 Tyr Trp Leu Ile Ile Arg Leu Pro Ile Leu Phe Ala Ile Gly Val Asn 305 310 315 320 Phe Leu Ile Phe Val Arg Val Ile Cys Ile Val Val Ser Lys Leu Lys 325 330 335 Ala Asn Leu Met Cys Lys Thr Asp Ile Lys Cys Arg Leu Ala Lys Ser 340 345 350 Thr Leu Thr Leu Ile Pro Leu Leu Gly Thr His Glu Val Ile Phe Ala 355 360 365 Phe Val Met Asp Glu His Ala Arg Gly Thr Leu Arg Phe Ile Lys Leu 370 375 380 Phe Thr Glu Leu Ser Phe Thr Ser Phe Gln Gly Leu Met Val Ala Ile 385 390 395 400 Leu Tyr Cys Phe Val Asn Asn Glu Val Gln Leu Glu Phe Arg Lys Ser 405 410 415 Trp Glu Arg Trp Arg Leu Glu His Leu His Ile Gln Arg Asp Ser Ser 420 425 430 Met Lys Pro Leu Lys Cys Pro Thr Ser Ser Leu Ser Ser Gly Ala Thr 435 440 445 Ala Gly Ser Ser Met Tyr Thr Ala Thr Cys Gln Ala Ser Cys Ser 450 455 460 <210> 16 <211> 476 <212> PRT <213> Homo sapiens <400> 16 Met Pro Pro Cys Gln Pro Gln Arg Pro Leu Leu Leu Leu Leu Leu Leu 1 5 10 15 Leu Ala Cys Gln Pro Gln Val Pro Ser Ala Gln Val Met Asp Phe Leu 20 25 30 Phe Glu Lys Trp Lys Leu Tyr Gly Asp Gln Cys His His Asn Leu Ser 35 40 45 Leu Leu Pro Pro Pro Thr Leu Val Cys Asn Arg Thr Phe Asp Lys Tyr 50 55 60 Ser Cys Trp Pro Asp Thr Pro Ala Asn Thr Thr Ala Asn Ile Ser Cys 65 70 75 80 Pro Trp Tyr Leu Pro Trp His His Lys Val Gln His Arg Phe Val Phe 85 90 95 Lys Arg Cys Gly Pro Asp Gly Gln Trp Val Arg Gly Pro Arg Gly Gln 100 105 110 Pro Trp Arg Asp Ala Ser Gln Cys Gln Met Asp Gly Glu Glu Ile Glu 115 120 125 Val Gln Lys Glu Val Ala Lys Met Tyr Ser Ser Phe Gln Val Met Tyr 130 135 140 Thr Val Gly Tyr Ser Leu Ser Leu Gly Ala Leu Leu Leu Ala Leu Ala 145 150 155 160 Ile Leu Gly Gly Leu Ser Lys Leu His Cys Thr Arg Asn Ala Ile His 165 170 175 Ala Asn Leu Phe Ala Ser Phe Val Leu Lys Ala Ser Ser Val Leu Val 180 185 190 Ile Asp Gly Leu Leu Arg Thr Arg Tyr Ser Gln Lys Ile Gly Asp Asp 195 200 205 Leu Ser Val Ser Thr Trp Leu Ser Asp Gly Ala Val Ala Gly Cys Arg 210 215 220 Val Ala Ala Val Phe Met Gln Tyr Gly Ile Val Ala Asn Tyr Cys Trp 225 230 235 240 Leu Leu Val Glu Gly Leu Tyr Leu His Asn Leu Leu Gly Leu Ala Thr 245 250 255 Leu Pro Glu Arg Ser Phe Phe Ser Leu Tyr Leu Gly Ile Gly Trp Gly 260 265 270 Ala Pro Met Leu Phe Val Val Pro Trp Ala Val Val Lys Cys Leu Phe 275 280 285 Glu Asn Val Gln Cys Trp Thr Ser Asn Asp Asn Met Gly Phe Trp Trp 290 295 300 Ile Leu Arg Phe Pro Val Phe Leu Ala Ile Leu Ile Asn Phe Phe Ile 305 310 315 320 Phe Val Arg Ile Val Gln Leu Leu Val Ala Lys Leu Arg Ala Arg Gln 325 330 335 Met His His Thr Asp Tyr Lys Phe Arg Leu Ala Lys Ser Thr Leu Thr 340 345 350 Leu Ile Pro Leu Leu Gly Val His Glu Val Val Phe Ala Phe Val Thr 355 360 365 Asp Glu His Ala Gln Gly Thr Leu Arg Ser Ala Lys Leu Phe Phe Asp 370 375 380 Leu Phe Leu Ser Ser Phe Gln Gly Leu Leu Val Ala Val Leu Tyr Cys 385 390 395 400 Phe Leu Asn Lys Glu Val Gln Ser Glu Leu Arg Arg Arg Trp His Arg 405 410 415 Trp Arg Leu Gly Lys Val Leu Trp Glu Glu Arg Asn Thr Ser Asn His 420 425 430 Arg Ala Ser Ser Ser Pro Gly His Gly Pro Pro Ser Lys Glu Leu Gln 435 440 445 Phe Gly Arg Gly Gly Gly Ser Gln Asp Ser Ser Ala Glu Thr Pro Leu 450 455 460 Ala Gly Gly Leu Pro Arg Leu Ala Glu Ser Pro Phe 465 470 475
Claims
1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from SEQ ID NOS: 9-11.
2. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating type 2 diabetes.
3. A pharmaceutical composition comprising: The compound of claim 1 or a pharmaceutically acceptable salt thereof; and Pharmaceutically acceptable carrier, diluent or excipient.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof for use in treating a disease selected from type 2 diabetes, dyslipidemia, metabolic syndrome, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and obesity.
5. The compound or pharmaceutically acceptable salt thereof according to claim 4, wherein the disease is type 2 diabetes or obesity.
6. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease selected from type 2 diabetes, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.
7. The use according to claim 6, wherein the disease is type 2 diabetes or obesity.
